Ocufen contains flurbiprofen sodium, a non-steroidal anti-inflammatory drug (NSAID), and is indicated for the inhibition of intraoperative miosis. The drug’s mechanism of action is believed to be through inhibition of the cyclo-oxygenase enzyme that is essential in the biosynthesis of prostaglandins. Prostaglandins have been shown to be mediators of certain kinds of intraocular inflammation.
Allergan has made a business decision to permanently discontinue manufacturing the branded, authorized generic, and a repackaged version of the branded drug. The affected NDCs are #11980-801-03, 60758-910-03, and 42254-023-025, respectively.
For more information call (800) 678-1605 or visit Allergan.com.